Home

Driving the Data-Rich Future of OSDs
Data-rich, data-led, data-driven — these terms increasingly define modern oral solid dose development. In this roundtable, industry leaders discuss what it will take to navigate this next phase of OSD innovation. read more
Peptide-to-Small-Molecule Translation
Recent advances are turning what was once a trial-and-error exercise into a disciplined and reproducible design workflow. read more
Particle Size Meets Chemistry
As material complexity and regulatory expectations grow, LD-PCRS correlative characterization will support robust formulation design, process control, and risk-based decision-making. read more
Handling Machinability Challenges with Hard Shell Capsules
Machinability issues linked to capsule-related factors can disrupt production, increase waste and jeopardize delivery timelines. read more

Servier Bets $2.65B on Edgewise Muscular Dystrophy Biz
June 01, 2026
The deal centers around Edgewise’s sevasemten, an investigative orally administered first-in-class fast skeletal myosin inhibitor. read more
BMS Oral CELMoD Candidate More Than Doubles Survival in Multiple Myeloma
June 01, 2026
Compared to the standard of care, the therapy led to a progression-free survival of 18 months vs. 8.3 months. read more
Shionogi Wins FDA Nod for First Oral Post-Exposure COVID Prevention
June 01, 2026
Between exposure and day 10, the drug reduced the risk of symptomatic COVID by 67%. read more